Mexidol, 5%, 2 ml, 50 pcs.

Mexidol® has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effect, increases resistance to stress. The drug increases resistance to the main damaging factors, to oxygen-dependent pathological states (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication by alcohol and antipsychotic drugs (neuroleptics)).

Mexidol® improves cerebral metabolism and blood supply of the brain, improves microcirculation and blood rheology, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets) in hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL. It reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of Mexidol® is due to its antihypoxant, antioxidant and membranoprotective actions. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid/protein ratio, reduces membrane viscosity and increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their ability to bind to ligands, helps maintain the structural and functional organization of biomembranes, neurotransport and improve synaptic transmission. Mexidol® increases dopamine content in the brain. Causes enhancement of compensatory activity of aerobic glycolysis and reduction of the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with increase of ATP, creatine phosphate and activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Mexidol® normalizes metabolic processes in ischemic myocardium, reduces the zone of necrosis, restores and improves myocardial electrical activity and contractility as well as increases coronary blood flow in ischemic area and reduces consequences of reperfusion syndrome in acute coronary failure. Increases antianginal activity of nitropreparations.

Mexidol® promotes the preservation of retinal ganglion cells and optic nerve fibers at progressive neuropathy caused by chronic ischemia and hypoxia. It improves the functional activity of the retina and the optic nerve, increasing visual acuity.

Pharmacokinetics

absorption<

When Mexidol® is administered in doses of 400-500 mg, the Cmax in plasma is 3.5-4.0 µg/mL and is reached within 0.45-0.5 h.

Distribution

The drug is detected in plasma for 4 hours after IUI. The average retention time of the drug in the body is 0.7-1.3 h.

Evacuation

Extracted from the body with urine mainly in glucuronconjugated form and in insignificant amounts in unchanged form.

Indications

acute impairment of cerebral circulation;

● brain injury, consequences of brain injuries;

●● dyscirculatory encephalopathy;

● vegetative dystonia syndrome;

mild cognitive disorders of atherosclerotic genesis;

● anxiety disorders with neurotic and neurosis-like conditions;

● acute myocardial infarction (from the first day) as part of complex therapy;

● primary open-angle glaucoma of different stages, as part of complex therapy;

● management of withdrawal syndrome in alcoholism with prevalence of neurotic and vegetative-vascular disorders;

● Acute intoxication with antipsychotic agents;

● Acute pyoinflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) in the complex therapy.

Active ingredient

Composition

Active substance:

Ethylmethylhydroxypyridine succinate 50 mg;

Auxiliary substances:

sodium metabisulfite – 0.4 mg,

water d/i – up to 1 ml.

How to take, the dosage

In/m or intravenously (by stream or dropwise).

In case of intravenous administration, water for injection is used as a solvent. Mexidol is administered by jetting for 5-7 minutes, by drip – at a rate of 60 drops per minute. Doses are adjusted individually.

The treatment starts with a dose of 0.05-0.1 g 1-3 times a day, gradually increasing dose to obtain therapeutic effect. Duration of treatment and choice of individual dose depends on severity of the patient’s condition and effectiveness of treatment. Maximum daily dose should not exceed 0.8 g.

For treatment of atherosclerotic dementia in elderly patients mexidol is prescribed in a 0.1-0.3 g/day dose.

In acute intoxication with neuroleptics the drug is administered by vein in a dose of 0.5-0.3 g/day.

In the complex treatment of acute pyo-inflammatory processes of the abdominal cavity (acute destructive pancreatitis, peritonitis) mexidol is prescribed in a single dose of 200 mg 3 times a day. In severe course of the disease the drug is diluted in 200 ml of physiological 0.9% sodium chloride solution and administered at a rate of 40-60 drops per minute. In a milder course of the disease mexidol is administered by injection/m. The course of treatment is 3-10 days.

Interaction

When used together, Mexidol increases the effect of benzodiazepine derivatives, antidepressants, anxiolytics, anti-Parkinsonian and anticonvulsants.

Mexidol reduces the toxic effects of ethanol.

Special Instructions

Mexidol can be combined with all drugs used to treat somatic diseases.

Pediatric use

Mexidol is not prescribed in children due to insufficient study of the drug action.

Impact on driving and operating machinery

When using the drug, caution must be exercised while driving motor vehicle and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

In individual cases, especially in predisposed patients with bronchial asthma with hypersensitivity to sulfites, severe hypersensitivity reactions may develop.

Contraindications

Strictly controlled clinical studies of safety of Mexidol® usage in children and during pregnancy and lactation have not been conducted.

Side effects

Digestive system: rarely – nausea, dry mouth.

Others: rare – allergic reactions.

Overdose

Symptoms: possible development of drowsiness.

Similarities